Search Results

Satsuma Pharmaceuticals, Inc. and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd., announced that five abstracts describing efficacy and safety results from the STS101 Phase 3 clinical study program were selected for presentation at the American Headache Society’s 66th Annual Scientific Meeting.

Satsuma Pharmaceuticals, Inc. announced that it has entered into a definitive agreement to be acquired by Shin Nippon Biomedical Laboratories, Ltd. for $0.91 in cash per share at the closing of the transaction plus one non-tradeable contingent value right of up to $5.77 per share.

Satsuma Pharmaceuticals, Inc . today announced that three abstracts highlighting STS101 were accepted at the American Academy of Neurology’s (AAN) 75th Annual Meeting.

After a quiet start to 2024, the FDA is expected to decide on three applications over the next two weeks, including one for a nasal powder migraine treatment.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) today announced that John Kollins, President and Chief Executive Officer, will deliver a company presentation during the SVB Securities Global Biopharma Conference, which is being held virtually February 14-16.

Topline results from the Phase III SUMMIT trial showed Satsuma Pharmaceuticals’ migraine candidate STS101 did not meet its primary efficacy endpoint.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the fourth quarter and full-year 2022 and summarized recent business highlights.

Satsuma Pharmaceuticals, Inc., and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd., announced that three abstracts describing efficacy and safety results from the STS101 Phase 3 efficacy trial were selected for presentation at the American Headache Society’s 65th Annual Scientific Meeting.